Elahere, which won initial U.S. Food and Drug Administration approval in 2022 for platinum-resistant ovarian cancer, was the key asset in AbbVie's $10.1 billion acquisition of biotech ImmunoGen that ...

Mirvetuximab soravtansine was the first ADC to show efficacy as a therapy for platinum-resistant ovarian cancer. Despite high expectations from early-phase studies, the drug initially did not meet the ...

Whooping cough cases are climbing at the fastest pace in years as students across America return to school, U.S. health ...

Plus: The story behind the award-winning science that led to Ozempic, the next astronaut launch and why homework is good for ...

Discover how advances from various biotechs are bridging treatment gaps in menopause care, offering hope for managing ...

Will neurotechnologies gradually invade the world of work? The question is worth asking, given the progress made in this ...

Indian equity markets witnessed a remarkable surge, with both the Sensex and Nifty reaching new record highs. This upward momentum was largely attributed to a rally in global markets following the U.S ...

Join Fox News for access to this content Plus special access to select articles and other premium content with your account - free of charge. By entering your email and pushing continue, you are ...

The highly anticipated 2024 European Society for Medical Oncology (ESMO) Annual Congress has taken place from September 13 to 17 in Barcelona, Spain. As one of the most influential annual gatherings ...